Antibody kits for selectively inhibiting VEGF
AssigneeBoard of Regents, The University of Texas System
InventorsPhilip E. Thorpe, Rolf A. Brekken
Life of this patent
Estimating the term…
Abstract
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Claims55
A kit comprising, in at least a first composition, at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF;
- and at least a second biological agent.
A kit comprising:
- (a) a biologically effective amount of at least a first purified, unconjugated anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF and that specifically inhibits VEGF binding to the VEGF receptor VEGFR2 (KDR/Flk-1) without significantly inhibiting VEGF binding to the VEGF receptor VEGFR1 (Flt-1);
- and
- (b) a biologically effective amount of at least a second biological agent.
A medicinal cocktail comprising, in a pharmaceutically acceptable form, a combined therapeutically effective amount of at least a first unconjugated anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF;
- and at least a second anti-angiogenic agent.
A composition comprising at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF.
A purified, unconjugated anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF.
A pharmaceutical composition comprising a biologically effective amount of at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF.
A liposomal formulation comprising at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that binds to substantially the same epitope as the monoclonal antibody 2C3 produced by hybridoma ATCC PTA 1595.
An ophthalmic formulation comprising at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that binds to substantially the same epitope as the monoclonal antibody 2C3 produced by hybridoma ATCC PTA 1595.
An ophthalmic preparation comprising an ophthalmic solution or suspension and at least a first purified anti-VEGF antibody, or antigen-binding fragment thereof, that effectively competes with the monoclonal antibody 2C3, produced by hybridoma ATCC PTA 1595, for binding to VEGF.
Dependencies are inferred from the claim text.